|
Summary of studies using the SF-36 to assess quality of life in patients with bipolar disorder1 |
|||||||||
| Study |
Patient population |
Physical |
Social |
Role physical |
Role emotional |
Pain |
Mental health |
General health |
Vitality |
|
|
|||||||||
| Arnold (2000) |
44 BD outpatients |
78.8 ± 22.4 |
57.9 ± 27.7 |
63.1 ± 41.6 |
38.6 ± 43.1 |
64.9 ± 25.7 |
55.3 ± 23.8 |
61.9 ± 25.4 |
43.6 ± 24.3 |
| Have (2002)2 |
93 BD type I 43 BD NOS |
89.6 91.2 |
73.6 80.8 |
77.6 81.7 |
69.5 80.6 |
74.1 82.5 |
62.3 68.7 |
62.6 68.2 |
58.0 62.0 |
| Leidy (1998) |
34 euthymic 28 depressed |
84.4 ± 20.2 72.2 ± 28.3 |
73.2 ± 18.2 29.3 ± 20.0 |
86.2 ± 28.0 32.3 ± 38.6 |
76.2 ± 31.2 8.3 ± 20.3 |
59.6 ± 29.0 54.7 ± 25.3 |
69.2 ± 17.9 33.4 ± 16.5 |
70.9 ± 20.7 58.0 ± 21.2 |
52.0 ± 16.2 20.4 ± 17.5 |
| Namjoshi (2002) |
122 BD type I (manic/mixed) 65 olanzapine 57 placebo |
86.8 ± 16.8 84.5 ± 21.9 |
47.1 ± 28.3 46.0 ± 31.8 |
70.4 ± 40.2 65.4 ± 40.3 |
37.4 ± 42.3 36.3 ± 43.3 |
68.4 ± 26.4 61.7 ± 25.0 |
59.9 ± 22.6 58.5 ± 19.8 |
69.0 ± 22.7 65.2 ± 24.3 |
63.3 ± 24.0 66.6 ± 20.0 |
| Patelis-Siotis (2001) |
34 BD CBT completers 8 BD CBT non-completers |
80.4 ± 19.3 63.8 ± 30.6 |
58.1 ± 25.0 46.9 ± 28.1 |
41.2 ± 39.8 40.6 ± 44.2 |
17.6 ± 33.1 29.2 ± 41.5 |
68.5 ± 23.7 63.4 ± 27.0 |
52.4 ± 18.0 44.0 ± 22.0 |
66.6 ± 21.7 46.4 ± 29.6 |
39.4 ± 19.3 28.1 ± 21.4 |
| Revicki (1997) |
14 BD patients (in-person) 14 BD patients (by telephone) |
78.4 ± 25.2 77.0 ± 29.3 |
53.6 ± 30.2 57.1 ± 29.9 |
65.2 ± 38.7 59.8 ± 41.0 |
40.5 ± 42.9 33.3 ± 40.6 |
68.0 ± 31.8 69.3 ± 28.2 |
53.4 ± 22.8 53.9 ± 20.0 |
59.8 ± 22.8 57.5 ± 22.7 |
41.4 ± 18.7 41.4 ± 20.5 |
| Tsevat (2000) |
53 BD patients |
78.7 ± 23.4 |
58.7 ± 27.9 |
63.2 ± 40.9 |
38.9 ± 42.3 |
65.3 ± 26.0 |
56.2 ± 23.7 |
62.1 ± 24.3 |
45.4 ± 24.4 |
| Shi (2002) |
453 BD type I 234 olanzapine 219 haloperidol |
85.2 ± 23.2 90.5 ± 15.7 |
61.1 ± 31.8 61.2 ± 29.1 |
66.1 ± 39.6 72.8 ± 36.3 |
53.3 ± 43.1 50.1 ± 43.7 |
79.8 ± 26.2 81.2 ± 26.1 |
71.0 ± 20.4 72.8 ± 16.5 |
73.6 ± 21.8 75.1 ± 19.2 |
75.8 ± 19.1 80.0 ± 14.9 |
| Shi (2004) |
573 BD type I (currently depressed) 250 olanzapine 58 olanzapine/fluoxetine combination 265 placebo |
65.8 ± 27.6 68.8 ± 25.0 66.6 ± 26.2 |
29.1 ± 20.9 30.6 ± 20.8 32.5 ± 21.4 |
47.8 ± 44.0 44.8 ± 41.8 46.4 ± 42.3 |
12.9 ± 25.4 9.8 ± 23.4 14.6 ± 28.7 |
60.6 ± 27.1 60.8 ± 25.6 57.8 ± 26.1 |
30.0 ± 16.1 31.0 ± 17.3 31.3 ± 15.7 |
51.1 ± 22.3 52.3 ± 20.7 48.6 ± 22.6 |
25.5 ± 17.5 25.3 ± 19.0 25.6 ± 17.6 |
| Yatham (2004) |
920 BD type I (currently depressed/ depressive episode in previous 60 days) |
70.2 ± 26.2 |
29.9 ± 22.8 |
36.7 ± 40.9 |
11.4 ± 23.5 |
62.2 ± 27.1 |
31.0 ± 17.3 |
47.5 ± 23.3 |
22.4 ± 17.7 |
|
1 Data presented as mean ± SD 2 SDs not available | |||||||||
Michalak et al. Health and Quality of Life Outcomes 2005 3:72 doi:10.1186/1477-7525-3-72 |
|||||||||